معرفی
Timothée Bruel is a researcher at the Institut Pasteur in Paris, France, working in the field of virology and immunology. He is part of the research team led by Olivier Schwartz, focusing on the mechanisms of humoral immune responses against HIV-1 and SARS-CoV-2. His work integrates both basic and translational research to understand antibody effector functions and viral immune evasion.
- Institution: Institut Pasteur, Paris
- Research Focus: Humoral Immunity, Neutralizing Antibodies, SARS-CoV-2, HIV-1, Vaccinology
- Collaborations: Olivier Schwartz Lab, Institut Pasteur Cambodia
His research interests center on the mechanisms of action of antibodies against viral pathogens, particularly HIV-1 and SARS-CoV-2. He investigates how antibodies neutralize viruses, mediate effector functions like ADCC, and how viral variants evolve to escape immune responses. His work also explores hybrid immunity resulting from vaccination and natural infection, with a focus on real-world populations including elderly individuals and Pacific Islanders.
The recent publications highlight a strong trend in studying SARS-CoV-2 variants (Omicron sublineages, B.1.640.1), neutralizing antibody responses, vaccine efficacy (especially BNT162b2), mucosal immunity, and cross-protection. His studies often involve longitudinal cohort analyses, serological assays, and viral neutralization tests, contributing to public health guidance on vaccination strategies.
Scientific contributions include:
- Characterization of hybrid immunity in Pacific Islanders post-vaccination and infection
- Analysis of Omicron subvariant resistance to monoclonal antibodies and vaccine-induced immunity
- Investigation of complement-dependent neutralization in mpox virus
- Assessment of neutralizing responses in vulnerable populations like nursing home residents
Timothée Bruel has been involved in advising on cohort design and data interpretation in multiple collaborative studies. His research is supported through institutional funding at the Institut Pasteur and collaborative grants related to emerging infectious diseases. He contributes to projects involving 3D visualization of biological data and viral pathogenesis modeling. His future work likely continues to focus on emerging variants, pan-coronavirus vaccines, and broad-spectrum antiviral antibodies.
